Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Figure S8 shows GSEA of PRMT5i- and G12Di-treated cells.

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Kristina Drizyte-Miller (14961288) (author)
Eará dahkkit:	Lars D. Engstrom (15089551) (author), Jeffrey A. Klomp (17646169) (author), Clint A. Stalnecker (14955952) (author), Addison G. Stamey (22247481) (author), Khalilah E. Taylor (17646166) (author), Mallory K. Roach (21351694) (author), Ryan Robb (21351697) (author), Laura M. Waters (22247484) (author), Andrew Calinisan (19771758) (author), Seamus Degan (22247487) (author), Wen-Hsuan Chang (22247490) (author), Xousaen M. Helu (22247493) (author), David Nguyen (22247496) (author), Elisa Baldelli (14961303) (author), Mariaelena Pierobon (14961309) (author), Emanuel F. Petricoin (14961327) (author), David M. Briere (17316311) (author), Jill Hallin (15046425) (author), James G. Christensen (15123507) (author), Kirsten L. Bryant (14955976) (author), Adrienne D. Cox (14953077) (author), Peter Olson (17316329) (author), Channing J. Der (14961333) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Cancer Biology Therapeutic Research and Development Drug Mechanisms Cellular responses to anticancer drugs Drug Targets Oncoprotein & tumor suppressor drug targets Gastrointestinal Cancers Pancreatic cancer Oncogenes & Tumor Suppressors Kras Small Molecule Agents HDAC & methyltransferase inhibitors
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i>-Deleted <i>KRAS</i>-Mutant Pancreatic Cancer